In a significant advancement in cancer immunotherapy research, scientists have identified the serotonin transporter (SERT)—commonly associated with the regulation of serotonin in the brain—as a novel immune checkpoint that negatively affects antitumor T cell activity. The finding could pave the way for innovative therapies aimed at enhancing immune system responses to cancer.
Traditionally, SERT’s primary known function has been to control serotonin levels in the central nervous system, where it influences mood, cognition, and other key physiological processes. However, new evidence suggests that SERT also plays a role in the immune system, particularly by modulating T cell responses during cancer progression.
By examining tumors and their immune microenvironments, researchers found that SERT expression is upregulated in certain immune contexts. This increase in SERT levels appears to blunt the efficacy of cytotoxic T cells, which are essential for targeting and destroying cancer cells. Blocking or interfering with SERT function in experimental models led to a reinvigoration of T cell responses and, consequently, enhanced antitumor activity.
These findings indicate that SERT functions as an immunoregulatory molecule beyond its classical role in neuronal signaling. As an immune checkpoint, it may represent a promising target for next-generation immunotherapies, potentially complementing existing therapies like PD-1 or CTLA-4 blockade, especially in patients who do not respond to current treatments.
Further research is warranted to better understand the mechanisms by which SERT modulates immune functions and to develop therapeutic strategies that can specifically inhibit its immune-suppressive activity without affecting its critical physiological roles in the nervous system.
This discovery broadens the landscape of immune regulation in oncology and reinforces the interconnectedness of neurological and immune systems in disease contexts.
Source: https:// – Courtesy of the original publisher.
